<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>Journal of Stem Cell Therapy and Transplantation</title>
<link>https://www.theskygallerypattaya.com/jsctt</link>
<description>A Heighpubs Open Access Journal</description>
<language>en-us</language>
	<item>
		<title>The rising role of mesenchymal stem cells in the treatment of COVID-19 infections</title>
		<pubDate>07/07/2020</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1021.php</link>
		<description>&amp;lt;p&amp;gt;Infectious diseases are a leading cause of death worldwide [1,2]. The Mid-20th century witnessed most of the antimicrobial discoveries but recently there is dramatic shortage of new classes of antimicrobial agents due to failure to build a sustainable antimicrobial discovery platform [1-4]. For example, antibiotics comprise Ë‚ 1.5% of the compounds under investigation at the major pharmaceutical and biotechnology companies [1,5].&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Neutrophils, NETs, NETosis and their paradoxical roles in COVID-19</title>
		<pubDate>05/11/2020</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1020.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;The pandemic of COVID-19 has adversely affected the world in many aspects. The health and economic sectors suffer most of the repercussions of this disease. The search for a cure for this rapidly spreading virus which is causing massive life losses worldwide requires clear understanding of the immunopathogenesis of this virus so as to develop pinpointed targeted therapies rather than relying mainly on supportive care measures and drug repurposing to fight this life-threatening virus infection.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;Neutrophils, neutrophil extracellular traps (NETs), and NETosis are not well studied not only in COVID-19, but also in coroviruses in general. The review will shed lights on the functions of neutrophils, NETs, and NETosis in various infectious complications as well as in sepsis and acute lung conditions in an attempt to understand their actual roles and in order to help in designing targeted therapies in the near future.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Autologous hematopoietic stem cell transplantation in systemic sclerosis patients</title>
		<pubDate>02/27/2020</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1019.php</link>
		<description>&amp;lt;h2&amp;gt;Editorial&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Systemic sclerosis (SScl) is an autoimmune disorder of unknown aetiology, characterised by fibrosis and microvascular injury of the affected organs. The hallmark of the disease is thickening and tightness of the skin and the subcutaneous tissue. SScl can affect virtually any organ systems, most importantly the skin, blood vessels, lungs, kidneys, gastrointestinal tract, and the heart [1].&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>A review on the occurrence of opportunistic infections after applications of stem cell techniques</title>
		<pubDate>12/18/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1018.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;In recent years, stem cells technology have been used widely in basic and clinical science researches LIPUS (low-intensity pulsed ultrasound) is another technique commonly used in conjunction with stem cells that can have complications after applications. One of the important issues in using this modern technique is the occurrence of opportunistic infections and inflammatory reactions in the rejection or destruction of these cells and in turn making ineffective of its applications, which have been reviewed in the following.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Natural killer cells in patients with hematologic malignancies, solid tumors and in recipients of hematopoietic stem cell transplantation</title>
		<pubDate>12/09/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1017.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Natural killer cells represent the first line of defense against infections and tumors and can be derived from various sources including: bone marrow, peripheral blood, specific types of human stem cells, and certain cell lines. The functions of natural killer cells are influenced by: several cytokines, activating and inhibitory receptors, as well as other immune cells such as dendritic cells and mesenchymal stem cells.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;Natural killer cells are attractive candidates for adoptive cellular therapy in patients with hematologic malignancies and solid tumors in addition to recipients of various forms of hematopoietic stem cell transplantation as they enhance antitumor effects without causing graft versus host disease. Several clinical trials have shown safety and efficacy of natural killer cell products obtained from autologous as well as allogeneic sources and used in conjunction with cytotoxic chemotherapy, monoclonal antibodies and novel agents.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;The following review, which includes extensive literature review on several aspects of natural killer cells, will give particular attention to: the rising role of natural killer cell therapies in patients with malignant hematological disorders, solid tumors and in recipients of stem cell therapies; preparation and manufacture of natural killer cell products; challenges facing the utilization of this form of cellular therapy including evolution of resistance; and maneuvers that can be employed to enhance the efficacy of natural killer cell therapies as well as suggested solutions to resolve the remaining challenges.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Human mesenchymal stem cells conditioned media promotes the wound healing process - An in vitro study</title>
		<pubDate>11/08/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1016.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Mesenchymal stem cells (MSCs) conditioned medium (CM) has a promising prospect towards skin regeneration. Therefore, human dental pulp and adipose stem cells (DPSCs and ADSCs) were isolated, propagated and evaluated for their stemness and genetic stability over time in culture before making CM. We aimed to characterize the applicability of lyophilized ADSCs and DPSCs derived CM (AD-CM and DP-CM) at 5 mg, 10 mg and 20 mg for wound healing process. The ability of wound closure was assessed by direct human dermal fibroblast cell scratch assay, treated with variable concentrations of AD-CM and DP-CM &amp;lt;em&amp;gt;in vitro&amp;lt;/em&amp;gt;. Additionally, we also assessed the expression of different cytokines and growth factors secreted from ADSCs and DPSCs in the CM relevant to the wound healing by cytokine array analysis. Our data demonstrates a significant effect of both the AD-CM and DP-CM in wound healing within 24 hrs compared to that in control.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>The rising role of natural killer cells in patients with malignant hematological disorders and in recipients of hematopoietic stem cell transplantation</title>
		<pubDate>10/01/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1015.php</link>
		<description>&amp;lt;h2&amp;gt;Introduction&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Natural killer (NK) cells, the third population of lymphoid cells, comprise 5%-25% of peripheral blood (PB) lymphocytes and represent the first line of defense against infections and tumors [1-7]. They can be derived from: bone marrow, PB, cryopreserved umbilical cord blood (UCB), human embryonic stem cells (hESCs), induced pluripotent stem cells (iPSCs), and various cell lines such as NK-92 and KHYG-1 [1].&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Advances in the use of GABAergic interneurons for the treatment of epilepsy</title>
		<pubDate>09/04/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1014.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Forebrain GABAergic neurons, the main inhibitory type of neuron in the cortex and hippocampus, represent a highly heterogeneous cell population that has been implicated in the predisposition to epilepsy and the onset of seizure. Earlier attempts to restore inhibition and reduce seizure in animal models of epilepsy have been carried out using embryonic basal forebrain tissue as source of immature GABAergic progenitors in cell-based therapies, with promising results. For therapeutic strategies this approach appears unrealistic, while the use of pluripotent stem cells to obtain immature GABAergic neurons opens new and promising avenues. Research on neural stem cells and pluripotent stem cells has greatly advanced and protocols have been established to efficiently direct progenitor cells to differentiate towards the GABAergic lineage. However, being highly heterogeneous, these neurons are difficult to be fully represented in vitro. Better knowledge on the expressed gene profiles, at single cell level, and the differentiation trajectory of these neurons will consent a more precise monitoring of the differentiation steps. Here we review the current literature about how to obtain and characterize genuine inhibitory neurons, how these can be grafted in animal models (and one day possibly in human) and which diseases could potentially be targeted and the efficiency of therapeutic outcome. The main obstacles that need to be overcome are: a) choice of an appropriate animal model, b) availability of human cells prone to GABA differentiation, c) the full representation of all IN subtypes, their proportions and their physiological activities, d) how to monitor them on the long-term after transplant.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Application of autologous adipose-derived stem cells for thin endometrium treatment in patients with failed ART programs</title>
		<pubDate>02/12/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1013.php</link>
		<description>&amp;lt;h2&amp;gt;Introduction&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;One of the factors of assisted reproduction technology (ART) success is an adequate growth and development of endometrium. At the end of follicular phase of menstrual cycle endometrium reaches its greatest thickness. It is believed that there is a critical limit of endometrial thickness beyond which the implantation of embryo is unlikely or impossible [1-5].&amp;amp;nbsp;In practice of ART programs ultrasound measurement of endometrial thickness is used to evaluate uterine lining growth. Scientific literature is debatable as to what thickness of endometrium should be considered optimal, some researchers emphasize the negative impact of &amp;amp;ldquo;thin endometrium&amp;amp;rdquo; on the success of ART programs [1-12], while others do not agree [6,7,9]. Nevertheless, when endometrial thickness in ART program does not exceed 6 mm the chance of pregnancy occurring is very low (Kumbak B, et al. 2009). Endometrium is a unique tissue that has thousands of cycles of growth, differentiation and detachment during woman&amp;amp;rsquo;s life [13-15]. Various organs and tissues are believed to contain stem cells populations that ensure the recovery of these tissues. Cells with multipotent properties were also found in endometrium [16,17]. A group of scientists from Australia detected and identified population of mesenchymal stem cells (MSCs) and epithelial progenitor cells in human endometrium [13,18-20]. It may be assumed that the absence, lack and defects of MSCs or the absence of signals needed to push their proliferation and differentiation lead to the fact that endometrium is not renewed, thin and unable to provide the implantation of embryo. Endometrial MSCs are adult stem cells similar to those found in other tissues. Therefore, in case of their lack or absence it is logical to assume that endometrial niche can be colonized by autologous stem cells derived from other tissues. In some areas of medicine, autologous stem cells are already used in clinical practice for the repair of damaged tissues and organs, although these methods are still experimental [21,22]. There were several publications about the use of stem cells for improving the endometrium growth and structure in experimental (animal) models (Zhao Jing et al. 2014) and in clinical practice in patients with Asherman syndrome and endometrial athrophy refractory to other types of therapy [23,24], (Singh N, et al. 2014; Santamariya X, et al. 2016). The main source of autologous stem cells is bone marrow. However, lately adipose tissue becomes popular because the procedure of its extraction - liposuction is less traumatic and better tolerated by patients compared to spongy bone puncture for bone marrow obtaining [25]. First MSCs were derived from adipose tissue during its cosmetic extraction in 2001 [26]. These adipose-derived mesenchymal stem cells (ASCs) have rather high capacity for differentiation (multipotency) and proliferation.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;The aim of this work was to study the possibility of autologous ASCs use for the treatment of &amp;amp;ldquo;thin endometrium&amp;amp;rdquo; in patients with unsuccessful ART programs.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;The protocol of treatment was approved by local ethical committee and patient&amp;amp;rsquo;s informed consent was obtained for it.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Preliminary Report on the Effect of Mesenchymal Stem Cell Therapy in Patients with Chronic Lung Allograft Dysfunction</title>
		<pubDate>08/28/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1012.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Background&amp;lt;/strong&amp;gt;: Mesenchymal stem cell (MSC) effects can shift immune responses toward anti-inflammatory and tolerogenic phenotypes, potentially helping patients with bronchiolitis obliterans syndrome (BOS).&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Methods&amp;lt;/strong&amp;gt;: We evaluated the effect of infusing allogeneic MSC intravenously in 9 patients with moderate BOS refractory to standard therapy who were not candidates for retransplant, dividing them into 3 dosing groups: Group 1, 1&amp;amp;times;106 MSC/kg (n=3); Group 2, 2&amp;amp;times;106 MSC/kg (n=3); and Group 3, 4&amp;amp;times;106 MSC/kg (n=3). We recorded pulmonary function tests, laboratory variables, and serum biomarkers pre- and post-MSC infusion.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Results&amp;lt;/strong&amp;gt;: These patients had significant decline in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) over 1 year pre-MSC infusion (mean &amp;amp;plusmn; SD) FVC, 3.11&amp;amp;plusmn;0.98 L, and FEV1 1.99+0.64 L versus FVC 2.58&amp;amp;plusmn;1.03 and FEV1 1.61&amp;amp;plusmn;0.52 just before infusion (P&amp;amp;lt;0.05); representing a mean loss of 530 mL in FVC and 374 mL in FEV1 over 12 months. One year post-MSC infusion, mean FVC and FEV1 increased to 2.66&amp;amp;plusmn;1.01 L and 1.63&amp;amp;plusmn;0.55 L, respectively (changes no longer significant compared to before MSC infusion). Patients in Group 1 showed elevation of tolerance-inducing T regulatory cells and increased levels of epidermal growth factor. Tolerance-inducing Th-2 cytokines increased in Groups 1 and 2. These changes were not significantly different in these small sub-groups.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusion&amp;lt;/strong&amp;gt;: MSC infusion appears to slow down or reverse the progressive decline in lung function in some patients with moderate BOS, possibly by inducing anti-inflammatory effects and promoting cell proliferation and angiogenesis.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>A flow perfusion bioreactor with controlled mechanical stimulation: Application in cartilage tissue engineering and beyond</title>
		<pubDate>06/13/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1011.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;To repair articular cartilage (AC) defects in osteoarthritic patients, one approach is to engineer threedimensional grafts with physicochemical properties similar to endogenous AC. Such grafts can be grown in bioreactors that provide environmental conditions favoring chondrogenesis.Studies show mechanical stimulation during the culturing process greatly enhances development of functional engineered grafts. A review of literature on bioreactor options reveals a lack of capacity to simultaneously stimulate cells with a combination of shear stress and oscillating hydrostatic pressure, both of which are important parts of the in vivo AC environment. It is hypothesized that combining both forces in a new bioreactor design will contribute to better AC tissue growth. In this paper, we provide a brief review of bioreactors and describe a new computer-controlled perfusion and pressurized bioreactor system, and the novelty of its control programming features for service in a host of applications. We briefly summarize results on synergistic effects in employing perfusion, oscillating hydrostatic pressure in a scaffold free environment and with the addition of encapsulation for inducing chondrogenesis. We further describe efforts to modify the newly developed system to include a continuous flow and pressurized centrifugal mode to enhance further the capabilities for inclusion of very high shear stresses. Applications for several other cell and tissue engineering approaches are discussed.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Stem cells in patients with heart failure experience</title>
		<pubDate>04/20/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1010.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Between 2003 and 2011, 17 patients with heart failure were treated with stem cells as part of our Foundation&amp;amp;rsquo;s Regenerative Medicine program. In several centers and countries 4 with ischemic cardiomyopathy of which 3 were surgically implanted with autologous bone marrow stem cells (ABMSC) plus bypass surgery.One patient was treated with hyperbaric medicine plus bypass surgery. Patients with idiopathic cardiomyopathy were implanted surgically with 2 different types of stem cells. Ten patients were implanted with stem cells derived from human fetuses (HFDSCs) and three patients with autologous bone marrow stem cells (ABMSC). The ejection fractions of the coronary artery bypass graft off pump OPCAB (control group) versus coronary artery bypass group off pump OPCAB plus stem cell transplantation were as followsin the entire serie: preoperative, 30.7% +/- 2.5% compared to 29.4% +/- 3.6%; 1 month, 36.4% +/- 2.6% versus 42.1% +/- 3.5%; 3 months, 36.5% +/- 3.0% vs. 45.5% +/- 2.2%; And 6 months, 37.2% +/- 3.4% versus 46.1% +/- 1.9% (p &amp;amp;lt;0.001). The first patient performed at our center in Argentina in this series is alive and asymptomatic 15 years after implantation, and the rest of this series we do not have current data. A patient without visible vessels in the anterior wall of the left ventricle was treated with 18 hyperbaric chamber sections from one hour at 1.4 AT. After creating angiogenesis, the patient was operated on receiving 2 grafts (mammary and venous) without extracorporeal circulation in the anterior descending artery and diagonal artery. The preoperative ejection fraction was 33% at 90 months of follow up the ejection fraction was 58%. The patient at 90 months was asymptomatic. Of the idiopathic heart disease group, nine patients underwent median sternotomy, and received human fetal stem cells (HFDSCs from ectopic pregnancy or spontaneous abortion, three patients received autologous bone marrow stem cells ABMSC) and 1HFDSCs for Minimally Invasive Surgery.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;Patients with HFDSC, compared to baseline, improved: The mean (&amp;amp;plusmn;SD) NYHA class decreased from 3.4 &amp;amp;plusmn; 0.5 to 1.33 &amp;amp;plusmn; 0.5 (P = 0.001); Mean EF increased 31%, from 26.6% &amp;amp;plusmn; 4.0% to 34.8% &amp;amp;plusmn; 7.2% (p = 0.005); the yield in ETT increased 291.3%, from 4.25 minutes to 16.63 minutes (128.9% in metabolic equivalents, 2.45 to 5.63) (P &amp;amp;lt;0.0001); the mean LVEDD decreased 15%, from 6.85 &amp;amp;plusmn; 0.6cm to 5.80 &amp;amp;plusmn; 0.58cm (P &amp;amp;lt;0.001); the mean performance on the 6-minute walk test increased 43.2%, from 251 &amp;amp;plusmn; 113.1 seconds to 360 &amp;amp;plusmn; 0 seconds (P = 0.01); the mean distance increased 64.4%, from 284.4 &amp;amp;plusmn; 144.9m to 468.2 &amp;amp;plusmn; 89.8m (P = 0.004); and the mean score in the Minnesota congestive HF test decreased from 71 &amp;amp;plusmn; 27.3 to 6 &amp;amp;plusmn; 5.9 (p &amp;amp;lt;0.001). Kaplan-Maier&amp;amp;rsquo;s probability of survival at 40 months was 66%. No rejection or cancer was observed at follow-up, in this series follow-up was discontinued at 4 years. In idiopathic patients receiving autologous cells by Mininvasive technique preoperative NYHA was 3.6 (+/- 0.70) 6 months after receiving stem cell therapy. The mean value of the functional class was 1.9 (+/- 0.90) (p &amp;amp;lt;0.005). ) showing marked clinical improvement. The preimplantation ejection fraction was 28% (+/- 3.6%) and at 6 months 44% (+/- 4.7%) (p &amp;amp;lt;0.005). There was a similar change in ventricular diameters: After 6 months LVESV went from 50mm (+/- 3.3) to 42mm (+/- 4.5) (p &amp;amp;lt;0.05). Two of the three patients in this group received re-synchronization therapy; one died at 10 years and 4 months, another at age 11 and another one alive at 12 years of the implant. More experience should be performed with different techniques and cells to find the appropriate treatment in this type of patients.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Stem cells in heart failure some considerations</title>
		<pubDate>01/25/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1009.php</link>
		<description>&amp;lt;h2&amp;gt;Short Communication&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Stem cell treatments depend not only on the type of cell to be used but also on the different implantation techniques. Intravascular cell injections are known to rapidly separate from the vessels. On the other hand, it is also well known that direct injection into the myocardium provides better coupling within the heart muscle. That were the cases of Embriofetal stem cell (HFDSC) or Autologous stem cells (ABMSC) in our experience focused on direct approaches. When we have to deal with different stimuli, such as parietal stress or direct myocardial injury leading to hemodynamic overload, the heart responds with hypertrophy, able to initially compensate for loss of function. Later, and over a long subclinical period, progressive dilation continues to be compensated for by varying degrees of hypertrophy.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Stemness of Mesenchymal Stem Cells</title>
		<pubDate>12/29/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1008.php</link>
		<description>&amp;lt;h2&amp;gt;Editorial&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Mesenchymal stem cells (MSCs) are multipotent adult stem cells that can self-renew and differentiate into a variety of cell types including chondrocytes, osteocytes and adipocytes. MSCs reside in bone marrow, adipose tissues, cord blood, peripheral blood, placenta, Wharton&amp;amp;rsquo;s jelly, fetal liver and lung among others. MSCs represent one of the most promising stem cells for regenerative medicine due to their multipotency, immunoprivileged properties and easy expansion in vitro. So far, MSCs are already in various phases of clinical application [1-4]. Their most immediate use is in the orthopedic context due to the clear demonstration of their ability to differentiate into bone and cartilage [5-8]. It has been 5 decades since Friedenstein et al described clonal and plastic adherent stromal cells from bone marrow in the 1960s [9,10]. Although there are a handful of genes suggesting possible MSC stemness markers, the molecular basis underlying MSC stemness, especially the key transcription factor to MSC stemness, is still poorly understood.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Intraepidermal Injections of Autologous Epidermal Cell Suspension: A new promising approach to Dermatological Disorders. Preliminary Study</title>
		<pubDate>12/07/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1007.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Regenerative medicine is a modern approach of dermatological treatment, using Epidermal Cells of the interfollicular epidermis (ESCs) for their effect in skin regeneration in chronic ulcers and burns, melanoma, vitiligo, junctional epidermolysis bullosa.Intraepidermal injections of autologous epidermal cell suspension can be a new and very promising treatment for many other cutaneous disorders as non-scarring alopecia (Alopecia Areata, Androgenic Alopecia) or scarring alopecia (Lichern Plano Pilaris alopecia, Discoid Lupus Erithematosus alopecia), anti-aging therapies. The intraepidermal injection of an autologous epidermal cell suspension is a simple, fast and safe surgical procedure: a small, thin portion of the epidermis of the patient undergoes a treatment where a suspension with all the cells collected from the epidermis and cultured for 7 days is injected into the skin. Our preliminary study shows that a suspension contains a significant number of viable cells that survive at day 7 in culture.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;Our research is ongoing and is focusing on the typing of the different cells in the suspension and evaluation of the presence and the nature of stem cells.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Nicotinamide as a treatment option of Age-Related Macular Degeneration</title>
		<pubDate>09/21/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1006.php</link>
		<description>&amp;lt;h2&amp;gt;Case Report&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Age related macular degeneration is a severe disease of mainly elderly people and leads to central vision loss because of the degeneration of the retinal pigment epithelium [1]. Genetic and environmental factors are responsible for the accumulation of extracellular material and deposit formation near the retinal pigment epithelial (RPE) layer, which leads to loss of photoreceptors and induction of chronic inflammation. The deposits are composed of lipids and proteins including many complement proteins, indicating the involvement of the complement system in the degenerative process and chronic inflammation [2]. So far there is no treatment for the dry form of AMD, except nutritional supplementation with antioxidants and vitamins [3]. Combined with a prolonged lifetime expectation in developed countries, AMD is developing to a social and economic burden. Therefore, there is an urgent need for a treatment of AMD that can delay disease manifestation and progression for several years.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Arid3a regulates mesoderm differentiation in mouse embryonic stem cells</title>
		<pubDate>09/07/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1005.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Research into regulation of the differentiation of stem cells is critical to understanding early developmental decisions and later development growth. The transcription factor ARID3A previously was shown to be critical for trophectoderm and hematopoetic development.Expression of ARID3A increases during embryonic differentiation, but the underlying reason remained unclear. Here we show that Arid3a null embryonic stem (ES) cells maintain an undifferentiated gene expression pattern and form teratomas in immune-compromised mice. However, Arid3a null ES cells differentiated in vitro into embryoid bodies (EBs) significantly faster than control ES cells, and the majority forming large cystic embryoid EBs. Analysis of gene expression during this transition indicated that Arid3a nulls differentiated spontaneously into mesoderm and neuroectoderm lineages. While young ARID3A-deficient mice showed no gross tissue morphology, proliferative and structural abnormalities were observed in the kidneys of older null mice. Together these data suggest that ARID3A is not only required hematopoiesis, but is critical for early mesoderm differentiation.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Enhancing adipose stem cell chondrogenesis: A study on the roles of dexamethasone, transforming growth factor Î²3 and ascorbate supplements and their combination</title>
		<pubDate>07/31/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1004.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Varied exogenous chondrogenic factors (CFs) are implicated in promoting differentiation of stem cells along a chondrocyte lineage in the field of regenerative tissue engineering for articular cartilage repair. The effects of dexamethasone, transforming growth factor &amp;amp;beta;3 (TGF-&amp;amp;beta;3), ascorbate, and their combinations, on mRNA expression in micromass-cultured human adipose derived stem cells (hADSCs) were investigated as a function of time.Indices include chondrogenic, hypertrophic, angiogenic, fibrogenic and osteogenic markers along with mechanical properties, assessed by atomic force microscopy. Early in the culture, i.e., at day three, no significant differences in mRNA expression of SOX9, aggrecan, lubricin, Col XI, Col X, vascular endothelial growth factor, Col I, and alkaline phosphatase were observed among samples treated with different CFs. However, significant differences in mRNA expression levels of pre-mentioned markers among samples treated with each CF exist when samples were supplied with the CFs for more than three days. A new indexing scheme summing expression of chondrogenic and subtracting non-chondrogenic angiogenic, fibrogenic and osteogenic marker levels shows dexamethasone is the overall leading CF among the factors and their combinations. Based on this scheme, we have projected not only the possible signaling pathways which might be affected by addition of CFs but also hypothetical indexes that may occur upon temporal variation of growth factor regimens.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Surgical Implantation of Stem Cells in Heart Failure Patients due to Idiophatic Cardiomyopathy</title>
		<pubDate>07/25/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1003.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Introduction&amp;lt;/strong&amp;gt;: Congestive heart failure is one of the main causes of morbidity and mortality in the XXI century given the promising to date of ABMDSCs and HFDSCs we investigate the safety and efficacy for the implantation of those stem cells for the treatment of idiopathic cardiomyopathy. This is the first pilot clinical study to assess the safety and feasibility of HFDSC in humans.&amp;amp;nbsp;We totally implanted 13 patients: 3 patients were implanted with ABMDSC by Mini-invasive surgical technique in March 2004 in Montevideo, Uruguay, and 10 patients were implanted with HFDSCs by using 2 different surgical techniques: minimally invasive technique (1 patient) and full sternotomy technique (9 patients) between January and February of 2005 in Guayaquil Ecuador.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;The HFDSCs were obtained from fetuses of 5 to 12 weeks&amp;amp;acute; gestation from legally consent, no compensated donors who have undergone terminated ectopic pregnancies, elective abortions, or spontaneous miscarriages. At that gestation&amp;amp;acute;s period, totipotent stem cells&amp;amp;acute; fetus haven&amp;amp;acute;t develop yet the HLA histocompatibility complex, so there&amp;amp;acute;s no possible antigenicity between donor and recipient.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Results&amp;lt;/strong&amp;gt;: Patients with HFDSCs improved in association with increased contractility in these regions. Compared with baseline assessments, we noted other improvements: The mean (&amp;amp;plusmn;SD) NYHA class decreased from 3.4&amp;amp;plusmn;0.5 to 1.33&amp;amp;plusmn;0.5 (P=.001); the mean EF increased 31%, from 26.6% &amp;amp;plusmn; 4.0% to 34.8%&amp;amp;plusmn;7.2% (P=.005); performance in the ETT increased 291.3%, from 4.25 minutes to 16.63 minutes (128.9% in metabolic equivalents, 2.45 to 5.63) (P&amp;amp;lt;.0001); the mean LVEDD decreased 15%, from 6.85&amp;amp;plusmn;0.6cm to 5.80&amp;amp;plusmn;0.58cm (P&amp;amp;lt;.001); mean performance in the 6-minute walk test increased 43.2%, from 251&amp;amp;plusmn;113.1 seconds to 360&amp;amp;plusmn;0 seconds (P=.01); the mean distance increased 64.4%, from 284.4&amp;amp;plusmn;144.9m to 468.2&amp;amp;plusmn;89.8m (P=.004); and the mean result in the Minnesota congestive HF test decreased from 71&amp;amp;plusmn;27.3 to 6&amp;amp;plusmn;5.9 (P&amp;amp;lt;.001) The Kaplan-Maier probability of survival at 48 months was 66%.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;It is not observed rejection, these patients have not developed malignance nodules or cancer at all in the follow-up. In the AMBCSs. The preoperative average NYHA functional class was 3.4; at. 6 months of follow up the average functional class value was 1.3 (p&amp;amp;lt;0,005);. After 6 months all of them remained in functional class I/II. Baseline values of LVEF were 25,28 and 30%.; at 6 months increased to 38, 40 and 46%. (p&amp;amp;lt;0,05). LVESV went from 50mm to 42mm (p&amp;amp;lt;0.05). After 24 months, 2 of the patients still maintained this improvement, while the 3er patient returned to the earlier values after suffering from pneumonia. At 12 years and 5 months 2 patients are alive both received a Resynchronization Therapy; at 8 years and 3 months and 9 years and 1,6 month the actual average EF are 28 and 30 %. The 3er patient died of sudden death at 10 years after the implantation. We can&amp;amp;acute;t demonstrate the cause of this sudden death.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusion&amp;lt;/strong&amp;gt;: Irrespective of the improvement seen in this study, it is still premature to determine accurately the mechanism of action, indications, doses and type of stem cells. Therefore, is imperative and extremely important that more research is needed.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;amp;nbsp;&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;amp;nbsp;&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;amp;nbsp;&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;amp;nbsp;&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Rhabdomyoblasts in Pediatric Tumors: A Review with Emphasis on their Diagnostic Utility</title>
		<pubDate>03/09/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1002.php</link>
		<description>&amp;lt;h2&amp;gt;SUMMARY&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Rhabdomyosarcoma is a soft tissue pediatric sarcoma composed of cells which show morphological, immunohistochemical and ultrastructural evidence of skeletal muscle differentiation. To date four major subtypes have been recognized: embryonal, alveolar, spindle cell/sclerosing and pleomorphic.All these subtypes are defined, at least in part, by the presence of rhabdomyoblasts, i.e. cells with variable shape, densely eosinophilic cytoplasm with occasional cytoplasmic cross-striations and eccentric round nuclei. It must be remembered, however, that several benign and malignant pediatric tumours other than rhabdomyosarcoma may exhibit rhabdomyoblaststic and skeletal muscle differentiation. This review focuses on the most common malignant pediatric neoplasm that may exhibit rhabdomyoblastic differentiation, with an emphasis on the most important clinicopathological and differential diagnostic considerations.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>The Femoral Head of Patients with Hip Dysplasia is not as Osteogenic as Iliac Crest Bone Location</title>
		<pubDate>12/03/2016</pubDate>
		<link>https://www.theskygallerypattaya.com/jsctt/jsctt-aid1001.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;When Total Hip Arthroplasty (THA) is required in a patient with developmental dysplasia of the hip (DDH), bone deficiency in the acetabular roof often remains a problem. The iliac crest (IC) has long been the preferred source of autograft material, but graft harvest is associated with frequent complications and pain. Autologous bone graft can also be obtained from the femoral head (FH) for reconstruction of the acetabulum in hip arthroplasty.&amp;amp;nbsp;However, in certain challenging clinical scenarios, incorporation of the femoral head autograft appears less successful than the iliac crest autograft. The difference in potential for proliferation and osteoblastic differentiation between the two sites has still not been evaluated; therefore, it is not known how to compensate for this difference when it is present. We designed this study to evaluate the number of mesenchymal stem cells (MSCs) in both the iliac crest and femoral head of the same patient. We also determined the best operating room procedure for loading the femoral head with MSCs to achieve equivalent numbers of MSCs as in the IC. Twenty patients (8 men and 16 women) undergoing THA for DDH were enrolled in the study. The mean age was 55.5 years (range 41&amp;amp;ndash;65 years). Bone marrow aspirates were obtained from three depths within the femoral head and the aspirates were quantified relative to matched iliac crest aspirates that were obtained from the same patient at the same time. The cell count, progenitor cell concentration (cells/mL marrow), and progenitor cell prevalence (progenitor cells/million nucleated cells) were calculated.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;Aspirates of FH marrow demonstrated less concentrations of mononuclear cells compared with matched controls from the iliac crest. Progenitor cell concentrations were consistently lower in FH aspirates compared to matched controls from the iliac crest (p = 0.05). The concentration of osteogenic progenitor cells was, on average, 40% lower in the FH aspirates than in the paired iliac crest samples (p = 0.05). However, with bone marrow aspirated from the iliac crest, we were able to load the femoral head autograft with sufficient MSCs to obtain the same number as present in an iliac crest. With concentrated bone marrow from the IC, supercharging the femoral autograft with MSCs to numbers above that present in the IC was possible in the operating room, and the number of MSCs supercharged in the femoral head was predictable.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;Based on these findings we suggest that FH graft supercharged with BM-MSCs from the IC is comparable to IC graft for osseous graft supplementation especially in THA for patients with DDH.&amp;lt;/p&amp;gt;</description>
	</item>
</channel>
</rss>